MX370905B - Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. - Google Patents

Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.

Info

Publication number
MX370905B
MX370905B MX2014009830A MX2014009830A MX370905B MX 370905 B MX370905 B MX 370905B MX 2014009830 A MX2014009830 A MX 2014009830A MX 2014009830 A MX2014009830 A MX 2014009830A MX 370905 B MX370905 B MX 370905B
Authority
MX
Mexico
Prior art keywords
weakly basic
drug delivery
delivery systems
solid solutions
basic drugs
Prior art date
Application number
MX2014009830A
Other languages
English (en)
Spanish (es)
Inventor
Lai Jin-Wang
Mapelli Luigi
Boltri Luigi
Venkatesh Gopi
Colombo Italo
Flabiani Flavio
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of MX370905B publication Critical patent/MX370905B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014009830A 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. MX370905B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84176006P 2006-08-31 2006-08-31
US84189306P 2006-08-31 2006-08-31
PCT/US2007/077153 WO2008027993A2 (en) 2006-08-31 2007-08-29 Drug delivery systems comprising solid solutions of weakly basic drugs

Publications (1)

Publication Number Publication Date
MX370905B true MX370905B (es) 2020-01-09

Family

ID=39136847

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014009830A MX370905B (es) 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
MX2009002166A MX2009002166A (es) 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009002166A MX2009002166A (es) 2006-08-31 2007-08-29 Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.

Country Status (12)

Country Link
US (3) US20080069878A1 (OSRAM)
EP (1) EP2056792B1 (OSRAM)
JP (2) JP5513113B2 (OSRAM)
KR (2) KR101468053B1 (OSRAM)
BR (1) BRPI0716196A2 (OSRAM)
CA (1) CA2661683C (OSRAM)
ES (1) ES2953390T3 (OSRAM)
IL (1) IL197204A0 (OSRAM)
MX (2) MX370905B (OSRAM)
NZ (1) NZ575171A (OSRAM)
RU (1) RU2434630C2 (OSRAM)
WO (1) WO2008027993A2 (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
KR101468053B1 (ko) 2006-08-31 2014-12-02 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
US20110070302A2 (en) * 2008-01-10 2011-03-24 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
JP2011509265A (ja) 2008-01-10 2011-03-24 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性物質のパルス放出が強化された、コーティングされた医薬製剤もしくはニュートラシューティカル製剤
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
PT2282779E (pt) * 2008-04-29 2013-05-28 Pharnext Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular
EP2286224A4 (en) * 2008-05-05 2012-04-25 Univ Winthrop Hospital METHOD FOR IMPROVING THE CARDIOVASCULAR RISK PROFILE OF COX-INHIBITORS
EP2285219B1 (en) * 2008-05-08 2018-07-18 Supernus Pharmaceuticals, Inc. Controlled release formulations of alprazolam
FR2938432B1 (fr) * 2008-11-14 2011-05-20 Debregeas Et Associes Pharma Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus
EA019583B1 (ru) * 2008-11-18 2014-04-30 Юсб Фарма, С.А. Композиции с пролонгированным высвобождением, содержащие производное 2-оксо-1-пирролидина
PL2358360T3 (pl) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
EP2374460A4 (en) * 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
MX388038B (es) 2008-12-19 2025-03-19 Supernus Pharmaceuticals Inc Uso de molindona para el tratamiento de agresión.
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
DK2391349T3 (da) * 2009-01-29 2014-11-03 Ucb Pharma Sa Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
US20110311626A1 (en) * 2009-02-23 2011-12-22 Gopi Venkatesh Controlled release compositions comprising anti-cholinergic drugs
WO2010096814A1 (en) * 2009-02-23 2010-08-26 Eurand, Inc. Controlled-release compositions comprising a proton pump inhibitor
CA2757979A1 (en) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
CN102549029B (zh) 2009-09-17 2015-03-04 巴斯夫欧洲公司 涂覆有含有活性物质的涂层的丸剂
FR2951378B1 (fr) * 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
JP5854476B2 (ja) 2009-11-30 2016-02-09 アデア ファーマスーティカルズ，インコーポレイテッド 圧縮性コーティングで被覆された医薬組成物及び錠剤並びに製造方法
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2011082426A1 (en) * 2010-01-04 2011-07-07 Eurand, Inc. Controlled release compositions comprising meclizine or related piperazine derivatives
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
CA2793222C (en) 2010-03-31 2018-01-23 Supernus Pharmaceuticals, Inc. Stabilized formulations of cns compounds
EP2563339A1 (en) * 2010-04-29 2013-03-06 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
AU2011256928A1 (en) * 2010-05-24 2012-12-20 Lupin Limited Extended release formulation of pramipexole
KR101828630B1 (ko) * 2010-07-09 2018-02-12 데이진 화-마 가부시키가이샤 구강 내 붕괴 정제
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
CN102440971A (zh) * 2010-10-15 2012-05-09 重庆市力扬医药开发有限公司 伊潘立酮口腔崩解片
ES2813859T3 (es) 2010-12-02 2021-03-25 Adare Pharmaceuticals Inc Gránulos de dispersión rápida, comprimidos de desintegración oral y métodos
CN102614140B (zh) * 2011-01-26 2015-11-25 浙江九洲药物科技有限公司 伊潘立酮口崩片及其制备方法
WO2012123963A2 (en) * 2011-02-24 2012-09-20 Megafine Pharma (P) Ltd. A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
EP2604256B1 (en) * 2011-12-14 2016-04-13 Hexal AG Multi layer coatings
WO2013156163A1 (en) * 2012-04-19 2013-10-24 Glatt Ag Taste-masked pharmaceutical compositions containing diclofenac
CA2884731C (en) * 2012-09-19 2016-11-01 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration with improved dissolution and/or absorption
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US9597339B2 (en) 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
HK1216513A1 (zh) * 2013-03-15 2016-11-18 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散劑型
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015141662A1 (ja) * 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
EP3122336A4 (en) 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
WO2016011335A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
PL3439649T3 (pl) * 2016-04-08 2024-03-18 Cereno Scientific Ab Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11439587B2 (en) * 2016-09-22 2022-09-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Injectable implants
JP2020508350A (ja) * 2017-02-21 2020-03-19 アイシーオー セラピューティクス インコーポレイテッド アンホテリシンｂの固体経口製剤
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
AU2019226030B2 (en) * 2018-02-21 2025-02-20 Aron H. BLAESI Expanding structured dosage form
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN113226313A (zh) * 2018-09-21 2021-08-06 卡希夫生物科学有限公司 包含三己芬迪的缓释组合物
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
US10679018B1 (en) 2019-02-05 2020-06-09 International Business Machines Corporation Magnetic tracking for medicine management
US10824822B2 (en) * 2019-02-05 2020-11-03 International Business Machines Corporation Magnetic tracking for medicine management
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN113350309B (zh) * 2021-08-09 2021-11-12 北京五和博澳药业股份有限公司 一种难溶性药物渗透泵控释片剂及其制备方法
US11648207B1 (en) * 2021-12-15 2023-05-16 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of Clozapine
US12303604B1 (en) * 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
JP3158435B2 (ja) * 1989-10-26 2001-04-23 日本新薬株式会社 徐放性製剤
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
JPH08208476A (ja) * 1995-02-01 1996-08-13 Kanebo Ltd ニフェジピン含有持続性製剤
DE69739967D1 (de) 1996-06-14 2010-09-30 Kyowa Hakko Kirin Co Ltd Eine im Mund schnell zerfallende Tablette
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
JP2000191519A (ja) * 1998-12-25 2000-07-11 Nippon Kayaku Co Ltd 薬効成分の不快な官能的性質が隠蔽された速放性粒状物
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
JP5062871B2 (ja) * 2003-05-13 2012-10-31 東和薬品株式会社 苦味を低減した口腔内崩壊錠剤
CA2547657A1 (en) 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
GB0419355D0 (en) 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US20060165788A1 (en) 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
KR101468053B1 (ko) * 2006-08-31 2014-12-02 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템

Also Published As

Publication number Publication date
JP2010502645A (ja) 2010-01-28
KR101468053B1 (ko) 2014-12-02
JP2013199488A (ja) 2013-10-03
US20140050797A1 (en) 2014-02-20
MX2009002166A (es) 2009-03-12
RU2434630C2 (ru) 2011-11-27
US10864166B2 (en) 2020-12-15
KR20090057410A (ko) 2009-06-05
EP2056792A4 (en) 2013-04-24
ES2953390T3 (es) 2023-11-10
US20080069878A1 (en) 2008-03-20
CA2661683C (en) 2015-11-24
CA2661683A1 (en) 2008-03-06
US20210046015A1 (en) 2021-02-18
NZ575171A (en) 2012-04-27
WO2008027993A3 (en) 2008-09-12
JP5913207B2 (ja) 2016-04-27
US12151028B2 (en) 2024-11-26
IL197204A0 (en) 2009-12-24
BRPI0716196A2 (pt) 2013-11-12
AU2007289235A1 (en) 2008-03-06
JP5513113B2 (ja) 2014-06-04
WO2008027993A2 (en) 2008-03-06
EP2056792B1 (en) 2023-06-07
RU2009111588A (ru) 2010-10-10
EP2056792A2 (en) 2009-05-13
KR20140114887A (ko) 2014-09-29

Similar Documents

Publication Publication Date Title
MX370905B (es) Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
WO2008011595A3 (en) Hydrophobic abuse deterrent delivery system
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
UA91376C2 (ru) Рецептура с контролируемым высвобождением
MX2011006578A (es) Formulaciones farmaceuticas de liberacion prolongada.
WO2008017867A3 (en) Antiretroviral solid oral composition with at least one water insoluble polymer
AU2007211091A8 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
MX2009004871A (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
BRPI0717509B8 (pt) sistema de liberação controlada para aplicação nasal de neurotransmissores
WO2008105773A3 (en) System for targeted delivery of therapeutic agents
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
MX2009004861A (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
FR19C1030I1 (fr) Systeme d'administration de medicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles
MX343358B (es) Tabletas de acetato de ulipristal.
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
MX2009003092A (es) Composiciones y metodos para suministro de farmaco dirigido a ph.
WO2013018050A3 (en) Dissolution enhanced controlled drug delivery system for poorly water soluble drugs
WO2006060325A3 (en) Coated drug delivery formulations
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof
HK1128633A (en) Drug delivery systems comprising solid solutions of weakly basic drugs
WO2021151442A3 (en) Methotrexate dosage form